Diabetes, Vol 37, Issue 4 405-412, Copyright © 1988 by American Diabetes Association

ARTICLES

Epidemiology of persistent proteinuria in type II diabetes mellitus. Population-based study in Rochester, Minnesota

DJ Ballard, LL Humphrey, LJ Melton, PP Frohnert, PC Chu, WM O'Fallon and PJ Palumbo
Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905.

Clinical risk factors for nephropathy were assessed in a population-based study of Rochester, Minnesota, residents with diabetes mellitus initially diagnosed between 1945 and 1969 (incidence cohort). The 1031 Rochester residents with non-insulin-dependent diabetes mellitus (NIDDM) were followed through their complete medical records in the community to 1 January 1982. The prevalence of persistent proteinuria was 8.2% at the diagnosis of NIDDM. Among those initially free of persistent proteinuria, the subsequent incidence was 15.3/1000 person-yr. Twenty years after the diagnosis of diabetes, the cumulative incidence of persistent proteinuria was 24.6%. A proportional hazards model identified the following risk factors for persistent proteinuria in NIDDM: elevated initial fasting blood glucose (P less than .01); older age at onset of diabetes (P less than .01); male gender (P = .05); and presence of macrovascular disease (P = .05), diabetic retinopathy (P = .05), or glycosuria (P = .07) at the diagnosis of diabetes. Separate analyses controlling for attained age indicated no association between duration of NIDDM and the incidence of persistent proteinuria. Stratified analysis of the two most significant risk factors (fasting blood glucose and age) indicated that hyperglycemia was a stronger risk factor for proteinuria in younger diabetic subjects, perhaps because of a competing risk of death in the elderly diabetic patient. In contrast to a recently described decreasing secular trend of proteinuria in Danish insulin-dependent diabetes mellitus patients, there was no decrease over the past 40 yr in proteinuria risk in this NIDDM incidence cohort.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]

				P. Gaede, L. Tarnow, P. Vedel, H.-H. Parving, and O. Pedersen Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria Nephrol. Dial. Transplant., November 1, 2004; 19(11): 2784 - 2788. [Abstract] [Full Text] [PDF]

				J. N. Cohn, A. A. Quyyumi, N. K. Hollenberg, and K. A. Jamerson Surrogate Markers for Cardiovascular Disease: Functional Markers Circulation, June 29, 2004; 109(25_suppl_1): IV-31 - IV-46. [Full Text] [PDF]

				M. C. Chapelsky, K. Thompson-Culkin, A. K. Miller, M. Sack, R. Blum, and M. I. Freed Pharmacokinetics of Rosiglitazone in Patients with Varying Degrees of Renal Insufficiency J. Clin. Pharmacol., March 1, 2003; 43(3): 252 - 259. [Abstract] [Full Text] [PDF]

				L. Foggensteiner, S. Mulroy, and J. Firth Management of diabetic nephropathy J R Soc Med, May 1, 2001; 94(5): 210 - 217. [Full Text] [PDF]

				M. B. Davidson How Do We Diagnose Diabetes and Measure Blood Glucose Control?: View 1: (Diagnosing) A Clinical Basis for the Diagnosis of Diabetes Diabetes Spectr, April 1, 2001; 14(2): 67 - 71. [Abstract] [Full Text] [PDF]

				D. KOYA, M. HANEDA, H. NAKAGAWA, K. ISSHIKI, H. SATO, S. MAEDA, T. SUGIMOTO, H. YASUDA, A. KASHIWAGI, D. K. WAYS, et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC {beta} inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes FASEB J, March 1, 2000; 14(3): 439 - 447. [Abstract] [Full Text]

				The CDC Diabetes Cost-Effectiveness Study Group The Cost-effectiveness of Screening for Type 2 Diabetes JAMA, November 25, 1998; 280(20): 1757 - 1763. [Abstract] [Full Text] [PDF]

				B. Gaster and I. B. Hirsch The Effects of Improved Glycemic Control on Complications in Type 2 Diabetes Arch Intern Med, January 26, 1998; 158(2): 134 - 140. [Abstract] [Full Text] [PDF]

				H. Miettinen, S. M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Proteinuria Predicts Stroke and Other Atherosclerotic Vascular Disease Events in Nondiabetic and Non–Insulin-Dependent Diabetic Subjects Stroke, November 1, 1996; 27(11): 2033 - 2039. [Abstract] [Full Text]

				D. M. Nathan The Pathophysiology of Diabetic Complications: How Much Does the Glucose Hypothesis Explain? Ann Intern Med, January 1, 1996; 124(1_Part_2): 86 - 89. [Abstract] [Full Text]

				R. Klein, B. E. K. Klein, and S. E. Moss Relation of Glycemic Control to Diabetic Microvascular Complications in Diabetes Mellitus Ann Intern Med, January 1, 1996; 124(1_Part_2): 90 - 96. [Abstract] [Full Text]

				D. M. Nathan Long-Term Complications of Diabetes Mellitus N. Engl. J. Med., June 10, 1993; 328(23): 1676 - 1685. [Full Text]

				A. M. Albisser and M. Sperlich Adjusting Insulins The Diabetes Educator, January 1, 1992; 18(3): 211 - 219. [PDF]